Updated NETs Clinical Trials

1. A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

   Conditions:   Metastatic Prostate Neuroendocrine Carcinoma;   Metastatic Prostate Cancer
   Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Carboplatin;   Drug: Cabazitaxel
   Sponsors:   Andrew J. Armstrong, MD;   Bristol-Myers Squibb
   Not yet recruiting

2. Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

   Condition:   Neuroendocrine Carcinoma
   Intervention:   Drug: Nab-paclitaxel Combined With Bevacizumab
   Sponsors:   Peking University;   Qilu Pharmaceutical Co., Ltd.
   Recruiting

3. Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

   Conditions:   Neuroendocrine Tumors;   Progesterone Receptor Positive Tumor;   Estrogen Receptor Positive Tumor
   Intervention:   Drug: Tamoxifen
   Sponsor:   AC Camargo Cancer Center
   Recruiting

4. Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

   Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
   Interventions:   Drug: Olaparib;   Drug: Durvalumab
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

5. Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 in Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors

   Conditions:   Neuroendocrine Tumor Grade 2;   Neuroendocrine Tumors
   Interventions:   Drug: Capecitabine Oral Product;   Drug: Temozolomide Oral Product;   Combination Product: transarterial radioembolization
   Sponsor:   University of Pennsylvania
   Not yet recruiting

6. Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

   Conditions:   Metastatic Large Cell Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Neoplasm;   Metastatic Small Cell Neuroendocrine Carcinoma
   Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

7. Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

   Conditions:   Neuroendocrine Tumors;   Carcinoid Syndrome;   Diarrhea
   Interventions:   Drug: Telotristat ethyl;   Drug: Peptide Receptor Radionuclide Therapy;   Other: Placebo
   Sponsors:   Pashtoon Kasi, MD, MS;   TerSera Therapeutics LLC
   Not yet recruiting

8. Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

   Conditions:   Advanced Digestive System Neuroendocrine Neoplasm;   Digestive System Neuroendocrine Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Neoplasm;   Midgut Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor;   Refractory Digestive System Neuroendocrine Neoplasm
   Intervention:   Drug: Abemaciclib
   Sponsors:   University of Washington;   National Cancer Institute (NCI);   Eli Lilly and Company
   Recruiting

9. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

   Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
   Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

10. Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

    Conditions:   Lung Small Cell Carcinoma;   Neuroendocrine Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Dostarlimab;   Drug: Niraparib
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting

11. Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

    Condition:   Gastroenteropancreatic Neuroendocrine Tumors
    Intervention:   Drug: arginine/lysine
    Sponsor:   Advanced Accelerator Applications
    Not yet recruiting

12. Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

    Conditions:   Neuroendocrine Tumors;   Progesterone Receptor Positive Tumor;   Estrogen Receptor Positive Tumor
    Intervention:   Drug: Tamoxifen 20 mg
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

13. Magnesium Sulfate and Neuroendocrine Hormone

    Conditions:   Arthropathy of Knee;   Magnesium Sulfate;   Cortisol;   Dehydroepiandrosterone
    Interventions:   Drug: Magnesium sulfate;   Drug: Isotonic Saline
    Sponsors:   Seoul National University Hospital;   Seoul National University Bundang Hospital
    Not yet recruiting

14. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

15. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

    Conditions:   Gastroenteropancreatic Neuroendocrine Tumors;   Pheochromocytoma;   Paraganglioma
    Intervention:   Drug: Lutetium [177Lu] oxodotreotide/dotatate
    Sponsor:   Advanced Accelerator Applications
    Not yet recruiting

16. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

17. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Breast Metaplastic Carcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Solid Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

18. 18F-DOPA II - PET Imaging Optimization

    Conditions:   Congenital Hyperinsulinism;   Neuroblastoma;   Parkinson Disease;   Lewy Body Disease;   Neuroendocrine Tumors;   Brain Tumor
    Interventions:   Drug: 18F-DOPA;   Drug: Furosemide Injection
    Sponsor:   University of Alberta
    Not yet recruiting

19. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

20. The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer

    Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: Ropivacaine;   Drug: Saline Solution
    Sponsors:   Karolinska Institutet;   Skane University Hospital
    Recruiting

21. Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

    Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Extensive Stage Lung Small Cell Carcinoma;   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Limited Stage Lung Small Cell Carcinoma;   Platinum-Resistant Lung Small Cell Carcinoma;   Platinum-Sensitive Lung Small Cell Carcinoma;   Prostate Small Cell Neuroendocrine Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Berzosertib;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

22. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

23. Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

    Conditions:   KRAS Gene Mutation;   Metastatic Colorectal Carcinoma;   NRAS Gene Mutation;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Carcinoma
    Interventions:   Drug: Binimetinib;   Drug: Palbociclib;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

24. Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

    Conditions:   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Non-Small Cell Squamous Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Neuroendocrine Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Large Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

25. Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

    Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Not yet recruiting

26. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

    Conditions:   Colorectal Cancer Not MSI-H or MMR-deficient;   GIST;   Oesophageal or Gastric Carcinoma;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Soft-tissue Sarcoma;   Thyroid Cancer;   Gastro-enteropancreatic Neuroendocrine Tumor;   Non-small Cell Lung Cancer;   Solid Tumor, Adult
    Interventions:   Drug: Phase 1 : Regorafenib;   Drug: Phase 1 : Avelumab;   Drug: Phase 2 : Regorafenib;   Drug: Phase 2 : Avelumab;   Drug: Phase 2: low-dose Regorafenib
    Sponsors:   Institut Bergonié;   Bayer;   Merck KGaA, Darmstadt, Germany
    Recruiting

27. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Recruiting

28. Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

    Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970 (M6620)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

29. Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

    Conditions:   Kidney Medullary Carcinoma;   Loss of INI 1 Protein Expression;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

30. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting

31. Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

    Condition:   Small-cell Lung Cancer
    Intervention:   Drug: HPN328
    Sponsor:   Harpoon Therapeutics
    Recruiting

32. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

33. Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer, STAMP Study

    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

34. Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

    Conditions:   Merkel Cell Carcinoma;   Skin Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting

35. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

36. Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

    Condition:   Vestibular Schwannoma
    Interventions:   Drug: intravenous fluorescein sodium;   Device: YELLOW 560 nm microscope filter (YE560)
    Sponsor:   Mayo Clinic
    Not yet recruiting

37. Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

    Conditions:   Neuroblastoma;   Pheochromocytoma
    Intervention:   Radiation: iobenguane I 131
    Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting

38. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Embryonal Carcinoma;   Immature Teratoma;   Malignant Teratoma;   Mixed Germ Cell Tumor;   Pineal Region Germ Cell Tumor;   Pineal Region Immature Teratoma;   Pineal Region Yolk Sac Tumor
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Mesna;   Biological: Pegfilgrastim;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Thiotepa
    Sponsor:   Children's Oncology Group
    Not yet recruiting